Innova Captab (INNOVACAP) Q1 24/25 earnings summary

Executive summary

• Integrated pharmaceutical business spanning R&D, manufacturing, distribution, marketing and exports; serves 100+ clients and exports to 25 countries.

• Q1 FY25 total income reached ₹296.4 crore, up 26.5% YoY, with growth plans centered on Jammu commissioning, exports and branded generics.

Financial highlights

• Revenue from operations was ₹294.3 crore and total income ₹296.4 crore, up 26.5% YoY and 10.5% QoQ.

• EBITDA was ₹44.3 crore, up 36.6% YoY; PAT was ₹29.5 crore, up 67.5% YoY.

• Consolidated PBT was ₹393.08m versus ₹245.99m in Q1 FY24; standalone revenue was ₹2,268.32m and profit ₹223.36m.

• Consolidated basic and diluted EPS was ₹5.15 versus ₹3.67 in Q1 FY24; standalone EPS was ₹3.90 versus ₹3.19.

Outlook and guidance

• Jammu commissioning is targeted for Q2 FY25, with revenue contribution expected from Q3; orders have been placed for the following year.

• Jammu is expected to reach optimum utilization in 3–4 years; management cited ₹800–900 crore revenue at 40%–50% utilization and ₹2,000 crore full top-line potential.

• Management expects revenue and bottom line to double within three years; FY growth is expected to exceed the 12%–15% analyst estimate, with margins at similar levels.

• Growth initiatives include 12+ formulations under preliminary research, three planned UK launches and six formulations in development for Europe.

• Panchkula R&D center plans focus on generic and complex generic products; Jammu margins are expected to improve from the second year.